Subscribe to NRx Newsletter

Press Releases

NeuroRx Partners with Leading Patient Advocacy Groups and Experts in the Bipolar Disorder Community to Launch 1st Global “Voice of the Patient” Survey to Gain Insights Into Care Received During Hospitalization for a Suicidal Crisis

Recent hospitalization is a risk factor for further suicide attempts — potentially related to patient care perceptions WILMINGTON, Del.–(BUSINESS WIRE)– NeuroRx launches the first global “Voice of the Patient Survey” for those diagnosed with bipolar disorder, in collaboration with leading patient advocacy groups, mental health advocates and expert opinion leaders. The strictly anonymous survey, seeking […]

NeuroRx to Take Part in Panel and Present at the Sachs Associates Neuroscience Biopartnering & Investment Forum on March 27th

Company developing NRX-101 – first potential biomarker-based oral treatment for Acute Suicidal Ideation & Behavior in Bipolar Depression Wilmington, Delaware , March 24, 2017 (GLOBE NEWSWIRE) — NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), today announced that Jonathan Javitt, M.D., M.P.H., Chief Executive Officer, […]

NeuroRx to Present at the Oppenheimer Annual Healthcare Conference on March 21st

Company developing NRX-101 – first potential biomarker-based oral treatment for Acute Suicidal Ideation & Behavior in Bipolar Depression Wilmington, Delaware , March 20, 2017 (GLOBE NEWSWIRE) — NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), today announced that Jonathan Javitt, M.D., M.P.H., Chief Executive Officer, […]

NeuroRx to Present at the BIO CEO & Investor Conference on February 13

Company developing NRX-101 – first potential treatment for Acute Suicidal Ideation in Bipolar Depression Wilmington, Delaware & Tel Aviv, Israel , Feb. 10, 2017 (GLOBE NEWSWIRE) — NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), today announced that Jonathan Javitt, Ph.D., M.D., Chief Executive Officer, […]

NeuroRx announces FDA IND clearance for NRX-101 phase 2b/3 study and publication of promising biomarker data

Clinical stage biopharma company advances development of first-in-class drug to decrease the risk of suicide in those suffering from bipolar depression SAN FRANCISCO, Jan. 4, 2017 /PRNewswire/ — Biotech Showcase at the JP Morgan Healthcare Conference NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB) in Bipolar […]

NeuroRx solidifies Intellectual Property Position – receives notice of Allowance by US Patent Office

Company with research operations in US and Israel seeks to develop first-in-class drug to decrease the risk of suicide in those suffering from depression WILMINGTON, Del. and TEL AVIV, Israel, Oct. 18, 2016 /PRNewswire/ — NeuroRx, a clinical-stage pharmaceutical company developing NRX-101 (CycluradTM), a first-in-class potentially breakthrough oral drug for the treatment of Acute Suicidal Ideation in […]

NeuroRx Announces Participation At The 18th Annual Rodman & Renshaw Global Investment Conference In New York City September 11-13, 2016

WILMINGTON, Del. and HAIFA, Israel, Sept 7, 2016 /PRNewswire/ — NeuroRx, a clinical-stage pharmaceutical company developing CycluradTM, a first-in-class, potentially breakthrough drug for the prevention of suicide in bipolar depression, announced today that it will be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., […]

NeuroRx Awarded First Prize in Annual Israel BIOMED Startup Competition

Company with research operations in US and Israel seeks to develop first-in-class drug to decrease the risk of suicide in those suffering from depression TEL AVIV, Israel–(BUSINESS WIRE)– NeuroRx, a clinical-stage pharmaceutical company developing a first-in-class potentially breakthrough drug for the prevention of suicide in bipolar depression, was awarded first prize in the annual startup […]

American Psychiatric Association Task Force Report Identifies Potential Value of NeuroRx Active Ingredient for Treatment of Depression

Findings note the transient nature of ketamine effects and paucity of promising experimental NMDA antagonists WILMINGTON, Delaware, October 21, 2015 /PRNewswire/ — The active ingredient of Cyclurad™ by NeuroRx, Inc has been identified as potentially promising in the treatment of depression in this month’s report by the American Psychiatric Association Task Force on Novel Biomarkers […]